Showing: 1 - 4 of 4 RESULTS

Prominent Journal of Medicine Makes Unprecedented Political Statement

There’s no doubt the scientific community has been struck with Trump Derangement Syndrome, but reading the latest screed against the administration over its coronavirus response raises questions about whose pocket one of the most prominent scientific journals may be in.

For the first time since its founding in 1812, The New England Journal of Medicine has taken a position on a presidential election. Titled “Dying in a Leadership Vacuum,” it’s no surprise which direction it’s taking, though it does not name either political candidate. What is surprising about its criticism, however, is how pro-China it is.

Right off the bat, we’re told about the “magnitude” of the administration’s failure in the U.S. in terms of the number of COVID-19 deaths — “far exceeding the numbers in much larger countries, such as China.” To claim this with a straight face, as if China is truthful about its death count, is beyond the pale. The U.S. intelligence community has warned the CCP is lying as have residents of Wuhan and countless others.

The editors then went on to not only criticize federalism but praise China’s authoritarian crackdown on citizens: “We know that we could have done better. China, faced with the first outbreak, chose strict quarantine and isolation after an initial delay. These measures were severe but effective, essentially eliminating transmission at the point where the outbreak began and reducing the death rate to a reported 3 per million, as compared with more than 500 per million in the United States.”

As a reminder, those “severe” measures included literally locking residents in their homes to stop the spread. 

There are other head-scratching criticisms found in the article, such as the editors’ chastisement of people who don’t wear masks, despite the Journal’s own admission in May that “wearing a mask outside health care facilities offers little, if any, protection from infection…In many cases, the desire for widespread masking is a reflexive reaction to anxiety over the pandemic.”

The Journal’s nearly three dozen editors urging Americans to “not abet them and enable the deaths of thousands more Americans by allowing them to keep their jobs,” follows other scientific journals taking a political stand this year. The Lancet and Scientific American also urged Americans to vote Trump out with the latter actually endorsing Joe Biden.

The Lancet and the NEJM took heat earlier this year after publishing a total fraud of a study on hydroxychloroquine that claimed patients with COVID were dying at higher rates than those who didn’t take it. The studies prompted WHO and other governments around the world to halt studies on the drug and change positions on prescribing it, potentially costing people their lives.

Source Article

New AHA Scientific Statement on Heart Health for LGBTQ Adults

Cardiovascular health should be routinely assessed and addressed in lesbian, gay, bisexual, transgender, and queer or questioning (LGBTQ) adults, the American Heart Association (AHA) concludes in a new scientific statement.

“Among the most important takeaways from this scientific statement is the need for healthcare providers in clinical settings to routinely assess sexual orientation and gender identity,” Billy A. Caceres, PhD, RN, chair of the statement writing group, told | Medscape Cardiology.

Billy A. Caceres, PhD, RN

“This will help healthcare providers engage LGBTQ patients in discussions about their heart health that account for the unique experiences of this population,” said Caceres, assistant professor, Columbia University School of Nursing, New York.

The statement was published online October 8 in Circulation.

“Invisible” Population

There are roughly 11 million LGBTQ adults in the United States, yet they are often “invisible in healthcare settings and cardiovascular research,” Caceres noted. The AHA scientific statement is the first from a national organization in the United States to comprehensively summarize the evidence on cardiovascular (CV) research in LGBTQ adults, he said.

There is mounting evidence that LGBTQ adults experience worse CV health relative to their cisgender heterosexual peers. Disparities in CV health may be driven by unique psychosocial stressors in the LGBTQ individuals such as family rejection and anxiety of concealment of their sexual orientation or gender identity.

While there is limited information on the CV health of LGBTQ people, the writing group says providers should be aware of the following:

  • LGBTQ adults are more likely to use tobacco than their cisgender heterosexual peers.

  • Transgender adults may be less physically active than their cisgender counterparts. Gender-affirming care might play a role in promoting physical activity among transgender people.

  • Transgender women may be at increased risk for heart disease due to behavioral and clinical factors (such as the use of gender-affirming hormones like estrogen).

  • Transgender women and nonbinary persons are more likely to binge drink.

  • Lesbian and bisexual women have a higher prevalence of obesity than heterosexual women do.

“We need to better understand how to support LGBTQ adults in optimizing their CV health. To do this, we will need rigorous research that examines potential explanations for the CV health disparities that have been observed in LGBTQ adults,” Caceres told | Medscape Cardiology.

He noted that research is also needed within the LGBTQ population among groups that might be at greater risk for heart disease, including racial and ethnic minority and low-income LGBTQ adults.

“Researchers should also design and test evidence-based interventions to promote the heart health of LGBTQ adults. This is an area that is greatly lacking within CV health research,” said Caceres.

Discrimination in Healthcare

Discrimination against LGBTQ adults in healthcare settings also remains a problem, the authors note.

The writing group cites data showing that nearly 56% of sexual minority and 70% of gender minority adults report having experienced some form of discrimination from clinicians, including the use of harsh/abusive language.

“Perhaps most alarming,” roughly 8% of sexual minority and 25% of transgender

ACGME Issues Statement on the Executive Order on Race and Sex Stereotyping

ACGME Issues Statement on the Executive Order on Race and Sex Stereotyping

PR Newswire

CHICAGO, Sept. 30, 2020

CHICAGO, Sept. 30, 2020 /PRNewswire/ — The ACGME today issued a statement on the Presidential Executive Order on Combating Race and Sex Stereotyping. The Order, issued September 22, 2020 seemingly promotes training of employees to create an inclusive environment by avoiding race and sex stereotyping; however, that intent is subverted by defining divisive concepts in a way that turns mechanisms intended to protect into weapons of divisiveness and exclusion. The Executive Order is inconsistent with work done over the past 50 years to advance civil rights of minoritized and thereby marginalized communities in the United States and, through its mandates, risks further division and fostering a culture of enmity. This approach works against the ACGME’s mission to improve both health and health care for patients and communities and ultimately results in worsening health outcomes for those we are dedicated to serve.


The ACGME has sought to advance the work of diversity, equity, and inclusion and the elimination of health disparities through its programs, policies, and requirements. The goal of the ACGME is to foster a professional, equitable, respectful, and civil environment that is free from discrimination, sexual and other forms of harassment, mistreatment, abuse, or coercion of students, residents, and faculty and staff members, for the betterment of patient care through its accreditation processes.

Prohibiting institutions from providing certain types of education and training that the Executive Order deems to be promoting racial and sexual stereotypes would have devastating consequences on educating residents and fellows toward the goal of eliminating disparities in health outcomes and achieving equity within the health care profession. The Executive Order would similarly preclude residency and fellowship programs from developing curricula that reflect the needs of their communities, particularly in those of color and women, and promote inclusivity.

Read the full ACGME statement.

The ACGME is a private, non-profit, professional organization responsible for the accreditation of over 12,000 residency and fellowship programs and the approximately 865 institutions that sponsor these programs in the United States. Residency and fellowship programs educate approximately 145,000 resident and fellow physicians in 157 specialties and subspecialties. The ACGME’s mission is to improve health care and population health by assessing and advancing the quality of resident physicians’ education through accreditation.


View original content to download multimedia:

SOURCE Accreditation Council for Graduate Medical Education

Source Article

CytRx Issues Statement Regarding Orphazyme’s Global Offering

CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today congratulated Orphazyme A/S (ORPHA.CO) (NASDAQ:ORPH) (“Orphazyme”) on the September 29, 2020 pricing of its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe. According to Orphazyme, the aggregate gross proceeds from its global offering will amount to approximately DKK 534,534,637 ($83,777,606 using a DKK/USD exchange rate of 6.3804) (assuming no exercise of the option to purchase additional shares) and DKK 614,714,770 ($96,344,237 using a DKK/USD exchange rate of 6.3804) (assuming full exercise of the option to purchase additional shares). CytRx has an agreement with Orphazyme that can yield milestone payments and royalties based on potential future sales of arimoclomol.

In connection with Orphazyme’s global offering, it disclosed receipt of a filing communication from the U.S. Food and Drug Administration (“FDA”) relating to the agency’s ordinary course review of its new drug application (“NDA”) for arimoclomol in the treatment of Niemann-Pick disease Type C (“NPC”). The filing communication follows acceptance on a Priority Review basis by the FDA of Orphazyme’s NDA for arimoclomol in NPC and the agency’s establishment of the Prescription Drug User Fee Act (“PDUFA”) target action date of March 17, 2021. Orphazyme stated that its receipt of the filing communication does not impact the FDA’s acceptance of its NDA, the target PDUFA action date or the Priority Review determination. Orphazyme’s disclosure notes that the filing communication constitutes preliminary notice from the FDA of potential review issues as part of its ordinary course review of the NDA and is not necessarily indicative of deficiencies that may be identified during the review. Orphazyme has stated that it intends to discuss the filing communication with the FDA.

In accordance with applicable securities laws, Orphazyme amended the registration statement on Form F-1 on file with the U.S. Securities and Exchange Commission. For further information concerning the FDA filing communication, we refer you to the “Recent Developments” section on Page 6 of Orphazyme’s amended Form F-1 filed on September 28, 2020.

CytRx will continue to provide updates that are relevant to its agreement with Orphazyme.

About CytRx Corporation

CytRx Corporation (OTCQB:CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S (Nasdaq Copenhagen exchange: ORPHA.CO) in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in four indications including amyotrophic lateral sclerosis (“ALS”), Niemann-Pick disease Type C (“NPC”), Gaucher disease and sporadic Inclusion Body Myositis (“sIBM”). Learn more at

About Orphazyme

Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life threatening or debilitating rare diseases. Their research focuses on developing therapies for diseases caused by misfolding of proteins including lysosomal storage diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four